Search Results 621-630 of 17256 for isotretinoin

1. Osteosarcoma - Doctors and departments - Mayo Clinic

   Learn about the symptoms and causes of this bone cancer that happens most often in children. Find out about treatments, including limb-sparing operations.

2. Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects - Mayo Clinic

   About this study. To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and ...

3. Breast cancer - Doctors and departments - Mayo Clinic

   Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

4. Breast cancer - Doctors and departments - Mayo Clinic

   Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

5. A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors - Mayo Clinic

   This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5 ...

6. Publications - James P. Utz, M.D. - Mayo Clinic

   Ingenito EP, Wood DE, Utz JP. Bronchoscopic lung volume reduction in severe emphysema. Proc Am Thorac Soc. 2008 May 1; 5(4):454-60. View PubMed; Swanson KL ...

7. A Study to Evaluate the Effectiveness and Safety of Pemigatinib in Previously-treated, Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) - Mayo Clinic

   A Study to Evaluate the Effectiveness and Safety of Pemigatinib in Previously-treated, Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor ...

8. Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation - Mayo Clinic

   Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type ...

9. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

10. Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study - Mayo Clinic

    In this study the investigators propose to use a daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM). This relatively small well-tolerated dose is likely to ...